Merck & Co. Inc. said on Wednesday that its angiotensin receptor blocker Cozaar (losartan) has received a UK licence for renal protection in patients with type 2 diabetes and nephropathy.
The new indication, also approved in the US in September, follows a study that found losartan reduced the risk of progression from renal disease to end-stage renal disease, in which dialysis or transplantation is required for survival, by 28%.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!